KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Working Capital Changes: 2010-2024

Historic Other Working Capital Changes for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Dec 2024 value amounting to $19.4 million.

  • Supernus Pharmaceuticals' Other Working Capital Changes rose 535.71% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $17.1 million, marking a year-over-year increase of 2214.91%. This contributed to the annual value of $19.4 million for FY2024, which is 5694.01% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Other Working Capital Changes of $19.4 million as of FY2024, which was up 5,694.01% from $334,000 recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Other Working Capital Changes ranged from a high of $19.4 million in FY2024 and a low of -$12.3 million during FY2022.
  • Over the past 3 years, Supernus Pharmaceuticals' median Other Working Capital Changes value was $334,000 (recorded in 2023), while the average stood at $2.5 million.
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first plummeted by 102.71% in 2023, then soared by 5,694.01% in 2024.
  • Supernus Pharmaceuticals' Other Working Capital Changes (MRY) stood at -$12.3 million in 2022, then soared by 102.71% to $334,000 in 2023, then soared by 5,694.01% to $19.4 million in 2024.
  • Its Other Working Capital Changes was $19.4 million in FY2024, compared to $334,000 in FY2023 and -$12.3 million in FY2022.